Fuller (FUL) Q3 2026 Earnings Call Transcript

H.B. Fuller reported fiscal Q3 2026 revenue of $938 million, up 5.2% year over year, while adjusted EBITDA rose 9% to $187 million and margin expanded 80bps to 19.9%; adjusted EPS increased 21% to $1.52. Organic revenue rose 4.4% as 7.4% pricing more than offset a 3.0% volume decline, with pricing and restructuring savings mitigating elevated raw-material costs. The company updated FY2026 adjusted EBITDA guidance to $655 million-$670 million and EPS guidance to $4.70-$4.85, while targeting $75 million of annualized Project Quantum Leap savings by 2030. Management expects the Advanced Medical Solutions acquisition to close by year-end, with leverage returning to 2.5x-3.0x EBITDA within two years, although electronics chip shortages, weak China demand, construction softness and disrupted petrochemical supply chains remain risks.

Analysis

FUL’s earnings quality is better than the headline growth suggests in the near term, but it remains price-led rather than demand-led. The key valuation question is whether customers absorb further price/cost lag without incremental volume attrition; a narrowing spread between realized pricing and delayed petrochemical costs makes FY27 margin expansion increasingly dependent on restructuring delivery. Facility closures also create execution risk: service disruptions or customer qualification losses could offset savings before the network reaches its lower-cost steady state.

The non-obvious catalyst is cash conversion, not EBITDA. Working-capital normalization, lower implementation capital, asset-sale proceeds and reduced maintenance spend can fund deleveraging faster than the income statement implies; this matters because the pending AMS financing should price materially above FUL’s historical borrowing cost. Conversely, inventory built for supply assurance is a concealed cash-flow risk if demand weakens in China, packaging, or electronics—destocking would pressure both volumes and operating cash flow simultaneously over the next 1-3 quarters.

AMS improves the mix toward a less cyclical, higher-growth medical exposure, but the market may be underpricing the leverage/multiple tradeoff until final financing terms are disclosed. A successful close and credible first-quarter post-close deleveraging path could rerate FUL as a specialty-healthcare/industrial hybrid over 6-18 months; a delayed close, debt cost above expectations, or a volume-led FY27 guide would instead expose a highly price-dependent earnings base. Watch January guidance for organic volume, price/raw-material spread, free-cash-flow conversion, and net leverage trajectory rather than EBITDA alone.

Key Decisions for Investors

• Initiate a modest long FUL only on post-results weakness or before the January FY27 framework if shares do not price in a volume recovery; target a 6-12 month hold through AMS close and early deleveraging evidence. Upside requires sustained margin/cash conversion plus medical mix rerating; cut or hedge if FY27 organic volumes remain below -2% or leverage guidance exceeds 3.0x beyond the stated two-year window.
• Prefer a FUL / short broad chemicals pair via long FUL and short XLB over 6-12 months for investors seeking idiosyncratic restructuring and medical-mix exposure while reducing commodity-beta risk. Exit if price/raw-material contribution turns negative for two consecutive quarters or closure-related service metrics deteriorate.
• Treat the debt-financing announcement as the near-term binary catalyst. If takeout funding clears near the indicated fixed-rate range and management provides a credible free-cash-flow bridge, add exposure; if financing costs widen materially or regulatory closing slips beyond year-end, avoid adding because deleveraging math and equity multiple both deteriorate.
• Monitor China electronics/EV demand and HHC customer order frequency monthly as downside alerts. A broader semiconductor supply normalization would support EA volumes within 1-3 quarters, while further China weakness would challenge the thesis that portfolio mix alone can restore organic volume growth.